Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
SOUTH SAN FRANCISCO, Calif., April 30, 2018 -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2018, and provide a general business overview on Wednesday, May 9, 2018, at 4:30 p.m. ET (1:30 p.m. PT).
Conference Call Details
The live conference call on Wednesday, May 9, 2018, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 7068059. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact:
Cara Miller
Portola Pharmaceuticals
[email protected]
Media Contact:
Laurie Masonson
Pure Communications
[email protected]
